Bayer Pakistan continues its women’s health focus by launching new medication to treat endometriosis

Aligned with “Health for All, Hunger for None,” Bayer expands access to endometriosis treatment for millions of women

Bayer Pakistan’s Pharmaceutical Division celebrated the commercial launch of a new product that adds to its women’s healthcare portfolio: an innovative medication approved to treat endometriosis.

Endometriosis is a painful, inflammatory condition affecting women of reproductive age (most commonly between 20 and 45 years old). It causes the endometrium (tissue similar to the uterine lining) to grow outside the uterus, leading to inflammation and the formation of scar tissue. It can cause chronic pelvic pain, heavy bleeding during or between periods, and fertility challenges.
 

Nationally, the prevalence of endometriosis is on the rise, with approximately 2.2 million women in Pakistan suffering from the condition. Despite its prevalence, endometriosis takes an average of 6-7 years to diagnose, meaning women endure years of unnecessary suffering.

Speaking at the occasion of the launch, Khurram Mirza, Country Commercial Lead of the Pharmaceutical Division of Bayer Pakistan, said:

We are very pleased to bring a new treatment option to women suffering from endometriosis. This condition seriously impacts well-being and quality of life for countless women. It also impacts women’s productivity and poses an economic burden for healthcare systems – these are all important considerations that require urgent solutions.

The team has worked hard to make this happen, and I am proud to say that today, we are truly living up to Bayer’s global mission, Health for All, Hunger for None, as a leader in women’s health.

Bayer is a global leader in the women’s health segment, and as part of its worldwide commitment to improving lives, the company intends to provide 100 million women in low-and-middle income countries with access to family planning by 2030.

In Pakistan, Bayer offers a wide range of contraceptive options, as well as therapies for various conditions affecting women’s reproductive health.

 

Bayer Pakistan remains committed to improving access to new and innovative therapies in Pakistan, thereby enhancing the quality of life for patients and advancing the overall health of the population.